Panacea Biotec Announces Special Window for Share Transfer and Dematerialization
Panacea Biotec has opened a special window for the transfer and dematerialization of physical shares. The window is open from February 05, 2026, to February 04, 2027. This facility is for shares sold/purchased before April 1, 2019, where transfer was not completed.
This is a standard procedural announcement related to share transfer facilitation and does not directly impact the company's operational or financial performance.
The announcement is a routine regulatory filing regarding a process for shareholders and does not contain any information that would positively or negatively impact the company's financials or operations.
Panacea Biotec Limited has informed the stock exchanges about a special window for the transfer and dematerialization of physical shares. This initiative is in accordance with a SEBI circular dated January 30, 2026.
The special window is open for a period of one year, commencing from February 05, 2026, and concluding on February 04, 2027. This facility is available to shareholders who sold or purchased shares prior to April 1, 2019, and who either did not lodge the shares for transfer or had lodged them but faced rejection or return due to documentation deficiencies or procedural issues.
Shareholders are advised to submit their transfer and dematerialization requests, along with original share certificates and other required documents, to the Company's Registrar and Share Transfer Agent, Vistra ITCL (India) Limited. Investors can refer to the SEBI circular for further details on the process. The company also requests shareholders to update their email addresses with the Company or RTA/Depository Participants.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.